Corcept Therapeutics Inc
NASDAQ:CORT

Watchlist Manager
Corcept Therapeutics Inc Logo
Corcept Therapeutics Inc
NASDAQ:CORT
Watchlist
Price: 57.54 USD 2.9% Market Closed
Market Cap: 6B USD
Have any thoughts about
Corcept Therapeutics Inc?
Write Note

Intrinsic Value

The intrinsic value of one CORT stock under the Base Case scenario is 63.25 USD. Compared to the current market price of 57.54 USD, Corcept Therapeutics Inc is Undervalued by 9%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CORT Intrinsic Value
63.25 USD
Undervaluation 9%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Corcept Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for CORT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about CORT?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Corcept Therapeutics Inc

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Corcept Therapeutics Inc

Provide an overview of the primary business activities
of Corcept Therapeutics Inc.

What unique competitive advantages
does Corcept Therapeutics Inc hold over its rivals?

What risks and challenges
does Corcept Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Corcept Therapeutics Inc recently?

Summarize the latest earnings call
of Corcept Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Corcept Therapeutics Inc.

Provide P/S
for Corcept Therapeutics Inc.

Provide P/E
for Corcept Therapeutics Inc.

Provide P/OCF
for Corcept Therapeutics Inc.

Provide P/FCFE
for Corcept Therapeutics Inc.

Provide P/B
for Corcept Therapeutics Inc.

Provide EV/S
for Corcept Therapeutics Inc.

Provide EV/GP
for Corcept Therapeutics Inc.

Provide EV/EBITDA
for Corcept Therapeutics Inc.

Provide EV/EBIT
for Corcept Therapeutics Inc.

Provide EV/OCF
for Corcept Therapeutics Inc.

Provide EV/FCFF
for Corcept Therapeutics Inc.

Provide EV/IC
for Corcept Therapeutics Inc.

Show me price targets
for Corcept Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Corcept Therapeutics Inc?

How accurate were the past Revenue estimates
for Corcept Therapeutics Inc?

What are the Net Income projections
for Corcept Therapeutics Inc?

How accurate were the past Net Income estimates
for Corcept Therapeutics Inc?

What are the EPS projections
for Corcept Therapeutics Inc?

How accurate were the past EPS estimates
for Corcept Therapeutics Inc?

What are the EBIT projections
for Corcept Therapeutics Inc?

How accurate were the past EBIT estimates
for Corcept Therapeutics Inc?

Compare the revenue forecasts
for Corcept Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Corcept Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Corcept Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Corcept Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Corcept Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Corcept Therapeutics Inc with its peers.

Analyze the financial leverage
of Corcept Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Corcept Therapeutics Inc.

Provide ROE
for Corcept Therapeutics Inc.

Provide ROA
for Corcept Therapeutics Inc.

Provide ROIC
for Corcept Therapeutics Inc.

Provide ROCE
for Corcept Therapeutics Inc.

Provide Gross Margin
for Corcept Therapeutics Inc.

Provide Operating Margin
for Corcept Therapeutics Inc.

Provide Net Margin
for Corcept Therapeutics Inc.

Provide FCF Margin
for Corcept Therapeutics Inc.

Show all solvency ratios
for Corcept Therapeutics Inc.

Provide D/E Ratio
for Corcept Therapeutics Inc.

Provide D/A Ratio
for Corcept Therapeutics Inc.

Provide Interest Coverage Ratio
for Corcept Therapeutics Inc.

Provide Altman Z-Score Ratio
for Corcept Therapeutics Inc.

Provide Quick Ratio
for Corcept Therapeutics Inc.

Provide Current Ratio
for Corcept Therapeutics Inc.

Provide Cash Ratio
for Corcept Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Corcept Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Corcept Therapeutics Inc?

What is the current Free Cash Flow
of Corcept Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Corcept Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Corcept Therapeutics Inc

Current Assets 467m
Cash & Short-Term Investments 380.3m
Receivables 59.7m
Other Current Assets 26.9m
Non-Current Assets 317.3m
Long-Term Investments 167.3m
PP&E 8.4m
Other Non-Current Assets 141.5m
Current Liabilities 126.2m
Accounts Payable 18.6m
Accrued Liabilities 107.6m
Non-Current Liabilities 19.2m
Other Non-Current Liabilities 19.2m
Efficiency

Earnings Waterfall
Corcept Therapeutics Inc

Revenue
628.6m USD
Cost of Revenue
-9.8m USD
Gross Profit
618.8m USD
Operating Expenses
-475.4m USD
Operating Income
143.4m USD
Other Expenses
-1.5m USD
Net Income
141.8m USD

Free Cash Flow Analysis
Corcept Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In Q3 2024, Corcept reported $182.5 million in revenue, up 48% year-over-year, raising its 2024 guidance to $675-$700 million. The company is advancing its proprietary drug, relacorilant, which showed significant improvements in managing Cushing syndrome, achieving better hypertension and glucose control. Patient responses were statistically meaningful, with systolic blood pressure improvements of 6.6 mmHg. Corcept anticipates FDA submission for relacorilant by year-end, further supported by substantial growth potential from increased awareness of Cushing syndrome. They aim to become a $3 billion business within five years, bolstered by trials in oncology and metabolic diseases.

What is Earnings Call?
Fundamental Scores

CORT Profitability Score
Profitability Due Diligence

Corcept Therapeutics Inc's profitability score is 78/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Positive Free Cash Flow
Positive Gross Profit
Positive 3-Year Average ROE
78/100
Profitability
Score

Corcept Therapeutics Inc's profitability score is 78/100. The higher the profitability score, the more profitable the company is.

CORT Solvency Score
Solvency Due Diligence

Corcept Therapeutics Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Long-Term Solvency
Low D/E
Short-Term Solvency
80/100
Solvency
Score

Corcept Therapeutics Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CORT Price Targets Summary
Corcept Therapeutics Inc

Wall Street analysts forecast CORT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CORT is 76.4 USD with a low forecast of 67.67 USD and a high forecast of 84 USD.

Lowest
Price Target
67.67 USD
18% Upside
Average
Price Target
76.4 USD
33% Upside
Highest
Price Target
84 USD
46% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for CORT?

Click here to dive deeper.

Dividends

Corcept Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for CORT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

CORT Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Corcept Therapeutics Inc Logo
Corcept Therapeutics Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

6B USD

Dividend Yield

0%

Description

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. The company is headquartered in Menlo Park, California and currently employs 238 full-time employees. The company went IPO on 2004-04-15. The firm operates through the discovery, development and commercialization of the pharmaceutical products segment. The company has marketed Korlym (mifepristone) for the treatment of patients suffering from Cushing’s syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Its cortisol activity can be modulated by a drug that competes with cortisol as it attempts to bind to the glucocorticoid receptor (GR). The Company’s ingredient, mifepristone, reduces the binding of excess cortisol to GR. Its compounds bind to GR but not the progesterone, estrogen, or androgen receptors.

Contact

CALIFORNIA
Menlo Park
149 Commonwealth Dr
+16503273270.0
www.corcept.com

IPO

2004-04-15

Employees

238

Officers

Co-Founder, President, CEO & Director
Dr. Joseph K. Belanoff M.D.
CFO & Treasurer
Mr. Atabak Mokari
President of Endocrinology
Mr. Sean Maduck
Chief Development Officer
Dr. William Guyer Pharm.D.
Chief Business Officer & Secretary
Mr. Gary Charles Robb
Chief Accounting & Technology Officer
Mr. Joseph Douglas Lyon
Show More
Chief Scientific Officer
Dr. Hazel Hunt Ph.D.
Chief Human Resources & Communications Officer
Ms. Amy Flood
President of Emerging Markets
Ms. Monica Tellado
President of Oncology
Mr. Roberto W. Vieira
Show Less

See Also

Discover More
What is the Intrinsic Value of one CORT stock?

The intrinsic value of one CORT stock under the Base Case scenario is 63.25 USD.

Is CORT stock undervalued or overvalued?

Compared to the current market price of 57.54 USD, Corcept Therapeutics Inc is Undervalued by 9%.

Back to Top